Sarepta Therapeutics Stock Total Debt
| S1RP34 Stock | BRL 40.08 0.39 0.96% |
Sarepta Therapeutics fundamentals help investors to digest information that contributes to Sarepta Therapeutics' financial success or failures. It also enables traders to predict the movement of Sarepta Stock. The fundamental analysis module provides a way to measure Sarepta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sarepta Therapeutics stock.
Sarepta |
Sarepta Therapeutics Company Total Debt Analysis
Sarepta Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Sarepta Therapeutics Total Debt | 1.1 B |
Most of Sarepta Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sarepta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Sarepta Therapeutics has a Total Debt of 1.1 B. This is 60.13% lower than that of the Healthcare sector and 237.72% higher than that of the Biotechnology industry. The total debt for all Brazil stocks is 79.37% higher than that of the company.
Sarepta Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sarepta Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sarepta Therapeutics could also be used in its relative valuation, which is a method of valuing Sarepta Therapeutics by comparing valuation metrics of similar companies.Sarepta Therapeutics is currently under evaluation in total debt category among its peers.
Sarepta Fundamentals
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 56.41 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 25.76 X | |||
| Price To Sales | 67.46 X | |||
| Revenue | 701.89 M | |||
| Gross Profit | (165.84 M) | |||
| EBITDA | (317.41 M) | |||
| Net Income | (418.78 M) | |||
| Cash And Equivalents | 1.74 B | |||
| Cash Per Share | 21.78 X | |||
| Total Debt | 1.1 B | |||
| Debt To Equity | 2.19 % | |||
| Current Ratio | 6.23 X | |||
| Book Value Per Share | 4.91 X | |||
| Cash Flow From Operations | (443.17 M) | |||
| Earnings Per Share | (22.24) X | |||
| Number Of Employees | 840 | |||
| Beta | 0.97 | |||
| Market Capitalization | 58.46 B | |||
| Total Asset | 3.15 B | |||
| Z Score | 31.8 | |||
| Net Asset | 3.15 B |
About Sarepta Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sarepta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Sarepta Stock
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.